. 2020 Jun 5;56:102815. doi: 10.1016/j.ebiom.2020.102815

Table 2.

Baseline characteristics associated with the risk of death.

	Univariate analysis			Multivariate analysis (N = 2014)
	HR	95% IC	p	aHR	95% IC	p
ART strategy: early vs. deferred	0.74	0.48–1.13	0.17	0.76	0.49–1.16	0.20
IPT strategy: yes vs. no	0.64	0.41–0.98	*0.04*	0.63	0.41–0.97	*0.03*
Sex: Male vs. female	1.50	0.94–2.39	0.08	1.39	0.86–2.24	0.17
Plasma HIV-1 RNA: ≥ 5 vs. < 5 log₁₀ copies/ml	2.10	1.38–3.21	*0.0006*	1.44	0.90–2.32	0.13
PBMC HIV-1 DNA: ≥ 3 vs. < 3 log₁₀ copies/10⁶ cells	2.67	1.68–4.22	*<0.0001*	2.09	1.24–3.52	*0.005*
CD4+ cell count:			0.18			0.31
350–500 vs. <350 cells/mm³	0.90	0.54–1.48	0.67	0.99	0.59–1.64	0.96
≥500 vs. <350 cells/mm³	0.60	0.34–1.06	0.08	0.68	0.37–1.21	0.19

Characteristics associated with the risk of death, sensitivity analysis N°1: replacing Temprano ART strategy with actual ART initiation
	Univariate analysis*			Multivariate analysis* N = 2014
	HR	95% IC	p	aHR	95% IC	p
ART really started ¹	0.91	0.54–1.52	0.71	0.78	0.46–1.34	0.37
IPT strategy: yes vs. no	0.64	0.41–0.98	*0.04*	0.63	0.41–0.97	*0.04*
Sex: Male vs. female	1.50	0.94–2.39	0.08	1.39	0.86–2.24	0.18
Plasma HIV-1 RNA: ≥ 5 vs. < 5 log₁₀ copies/ml	2.10	1.38–3.21	*0.0006*	1.44	0.89–2.32	0.13
PBMC HIV-1 DNA: ≥ 3 vs. < 3 log₁₀ copies/10⁶ cells	2.67	1.68–4.22	*<0.0001*	2.12	1.26–3.57	*0.005*
CD4+ cell count:			0.18			0.26
350–500 vs. <350 cells/mm³	0.90	0.54–1.48	0.67	0.97	0.58–1.61	0.89
≥500 vs. <350 cells/mm³	0.60	0.34–1.06	0.08	0.64	0.36–1.17	0.15

Characteristics associated with the risk of death, sensitivity analysis N°2: patients randomized to deferred ART strategy with follow-up censored at ART initiation
	Univariate analysis*			Multivariate analysis* N = 1004
	HR	95% IC	p	aHR	95% IC	p
IPT strategy: yes vs. no	0.35	0.14–0.90	*0.029*	0.32	0.13–0.83	*0.018*
Sex: Male vs. female	1.47	0.60–3.57	0.40	1.38	0.55–3.50	0.49
Plasma HIV-1 RNA: ≥ 5 vs. < 5 log₁₀ copies/ml	4.75	2.01–11.2	*0.0004*	2.68	1.07–6.69	*0.035*
PBMC HIV-1 DNA: ≥ 3 vs. < 3 log₁₀ copies/10⁶ cells	7.25	2.45–21.42	*0.0003*	4.99	1.57–15.82	*0.006*
CD4+ cell count:			0.31			0.37
350–500 vs. <350 cells/mm³	0.92	0.29–2.92	0.89	0.90	0.28–2.90	0.86
≥500 vs. <350 cells/mm³	0.48	0.14–1.62	0.24	0.48	0.14–1.72	0.26

N : number of patient; HR : Hazard ratio; aHR : adjusted Hazard ratio (Adjusted for study centre and for all other variables shown in the table); ART: antiretroviral treatment; IPT : Isoniazid preventive therapy; CI: confidence interval; PBMC: Peripheral Blood Mononuclear Cells; DNA: deoxyribonucleic acid; RNA: ribonucleic acid.

*Cox proportional hazards models; N : number of patient; aHR : adjusted Hazard ratio (adjusted for study centre and for all other characteristics shown in the table); IPT : Isoniazid preventive therapy; CI: confidence interval: PBMC: Peripheral Blood Mononuclear Cells; DNA: deoxyribonucleic acid; RNA: ribonucleic acid; (1): ART was started vs. ART was never started (time dependant variable) during trial and post-trial follow-up.

*Cox proportional hazards models ; N : number of patient; aHR : adjusted Hazard ratio (adjusted for study centre and for all other characteristics shown in the table); IPT: Isoniazid preventive therapy; CI: confidence interval: PBMC: Peripheral Blood Mononuclear Cells; DNA: deoxyribonucleic acid; RNA: ribonucleic acid.